Daniel Morgensztern

Daniel Morgensztern's AcademicInfluence.com Rankings

Daniel Morgensztern

Philosophy

#8904

World Rank

#12374

Historical Rank

Logic

#5914

World Rank

#7368

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Daniel Morgensztern Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Daniel Morgensztern's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The biology and management of non-small cell lung cancer (2018) (2193)
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. (2006) (1585)
Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey (2007) (427)
PI3K/Akt/mTOR pathway as a target for cancer therapy (2005) (425)
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. (2021) (423)
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas (2017) (391)
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. (2017) (347)
Genomic alterations in lung adenocarcinoma. (2015) (276)
Prognostic biomarkers in diffuse large B-cell lymphoma. (2006) (249)
Immunotherapy in Lung Cancer. (2017) (210)
Clinical next‐generation sequencing in patients with non–small cell lung cancer (2015) (197)
NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. (2018) (195)
Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base. (2015) (187)
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study (2019) (159)
Distinctive Characteristics of Non-small Cell Lung Cancer (NSCLC) in the Young: A Surveillance, Epidemiology, and End Results (SEER) Analysis (2010) (155)
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (147)
Treatment advances in small cell lung cancer (SCLC) (2017) (141)
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. (2015) (123)
Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer (2012) (118)
Non–small‐cell Lung Cancer With Brain Metastasis at Presentation (2018) (108)
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer (2018) (92)
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. (2018) (83)
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 (2021) (83)
Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. (2019) (76)
Improving Survival for Stage IV Non-small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Survey from 1990 to 2005 (2009) (76)
Squamous cell cancer of the head and neck with distant metastasis at presentation (2011) (72)
Primary plasma cell leukemia (2009) (69)
MET Mutation Associated with Responsiveness to Crizotinib. (2015) (66)
Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC (2016) (62)
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. (2019) (61)
Waldenström macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005 (2012) (61)
Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer (2016) (60)
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. (2018) (59)
Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study (2018) (59)
The Effect of FDG-PET on the Stage Distribution of Non-small Cell Lung Cancer (2008) (55)
Rovalpituzumab tesirine , a DLL 3-targeted antibody-drug conjugate , in recurrent small-cell lung cancer : a fi rst-inhuman , fi rst-in-class , open-label , phase 1 study (2016) (54)
Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey from 1998 to 2003 (2012) (53)
Primary hepatic non-Hodgkin's lymphomas: case report and review of the literature (2003) (51)
Barriers to Enrollment in Non-small Cell Lung Cancer Therapeutic Clinical Trials (2011) (46)
Chemotherapy for Advanced-Stage Non–Small Cell Lung Cancer (2015) (45)
US breast cancer mortality trends in young women according to race (2015) (42)
Pulmonary marginal zone lymphoma: A single centre experience and review of the SEER database (2008) (41)
EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. (2008) (36)
EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer. (2015) (34)
Treatment Outcomes in Stage I Lung Cancer: A Comparison of Surgery and Stereotactic Body Radiation Therapy (2015) (34)
Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma (2007) (33)
National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non–Small-Cell Lung Cancer (2014) (32)
Brain Metastases at Presentation in Patients With Non–Small Cell Lung Cancer (2015) (31)
Immune checkpoint inhibition in patients with brain metastases. (2016) (28)
Role for Surgical Resection in the Multidisciplinary Treatment of Stage IIIB Non-Small Cell Lung Cancer. (2015) (28)
Patterns of care in hilar node-positive (N1) non-small cell lung cancer: A missed treatment opportunity? (2016) (28)
Radiation Recall Dermatitis Induced by Methotrexate in a Patient With Hodgkin’s Disease (2000) (27)
Review of Ongoing Clinical Trials in Non-small Cell Lung Cancer: A Status Report for 2009 from the ClinicalTrials.gov Website (2010) (27)
Use of new treatment modalities for non-small cell lung cancer care in the Medicare population. (2013) (27)
Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). (2016) (26)
Evaluation of Novel Orthotopic Nude Mouse Models for Human Small-Cell Lung Cancer (2013) (24)
Central nervous system toxicities of chemotherapeutic agents (2014) (23)
RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer (2019) (23)
Multidisciplinary Treatment for Stage IIIA Non-Small Cell Lung Cancer: Does Institution Type Matter? (2015) (23)
Percutaneous Image-Guided Ablation in the Treatment of Osseous Metastases from Non-small Cell Lung Cancer (2017) (22)
Prevalence of Hepatitis C Infection in Patients with Non-Hodgkin's Lymphoma in South Florida and Review of the Literature (2004) (21)
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations (2019) (20)
Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer. (2017) (19)
Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma. (2013) (19)
A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab ± Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer. (2021) (19)
Primary Diffuse Large Cell Lymphoma of the Mandible (2004) (18)
Thoroughness of Mediastinal Staging in Stage IIIA Non-small Cell Lung Cancer (2012) (18)
Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer (2011) (18)
7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC) (2015) (17)
Genomic Profiling of Lung Adenocarcinoma in Never-Smokers (2021) (17)
Primary lymphoblastic B-cell lymphoma of the cranial dura mater: a case report and review of the literature (2005) (16)
Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer. (2017) (16)
High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnos (2010) (16)
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma (2021) (16)
Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474 (2006) (15)
Is There a Role for Cetuximab in Non–Small Cell Lung Cancer? (2007) (15)
ORAL02.01: Safety and Efficacy of Single‐Agent Rovalpituzumab Tesirine, a DLL3‐Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology (2016) (15)
Non – Small Cell Lung Cancer, Version 3.2022 (2022) (15)
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. (2010) (14)
Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status. (2019) (14)
Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non–Small Cell Lung Cancer (2018) (13)
Brief Report: A Phase 1 Study Evaluating Rovalpituzumab Tesirine (Rova-T) in Frontline Treatment of Patients With Extensive-Stage Small Cell Lung Cancer. (2021) (13)
Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era? (2015) (13)
Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy (2014) (13)
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma (2019) (12)
Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC. (2019) (11)
Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014 (2020) (11)
A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer (2016) (11)
Immunogenicity of Influenza Vaccination in Patients With Cancer (2015) (10)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma (2022) (10)
The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis. (2015) (10)
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. (2019) (10)
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC) (2018) (10)
Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors. (2021) (9)
Primary Non-Hodgkin’s Lymphoma of the Lung. (2007) (9)
A prospective study on the incidence of delayed nausea and vomiting following administration of carboplatin-containing regimens for treatment of cancer without prophylactic aprepitant. (2008) (9)
Treating locally advanced disease: an analysis of very large, hilar lymph node positive non-small cell lung cancer using the National Cancer Data Base. (2014) (9)
Somatostatin Receptor Scintigraphy in MALT Lymphoma of the Lacrimal Gland Treated with Rituximab (2004) (9)
MA 02.10 Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC (2017) (9)
Molecularly targeted therapies in locally advanced non-small-cell lung cancer. (2013) (8)
Vaccines and Immunotherapy for Non-small Cell Lung Cancer (2010) (8)
Delayed nausea and vomiting from carboplatin doublet chemotherapy (2016) (8)
Comprar Devita, Hellman, And Rosenberg's Cancer. Principles And Practice Of Oncology. Review 4th Ed. | Ramaswamy Govindan | 9781496310804 | Lippincott Williams & Wilkins (2016) (8)
Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) Focus on Tumor Biology and Biomarkers Related to Lung Cancer (2011) (8)
A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer. (2014) (8)
Adjuvant Chemotherapy for Patients with T2N0M0 Non-small-cell Lung Cancer (NSCLC). (2015) (8)
Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors. (2016) (8)
Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology. (2008) (8)
Lack of survival improvement in patients with peripheral T-cell lymphoma: a Surveillance, Epidemiology, and End Results analysis (2011) (8)
A Phase I Study of Pegylated Liposomal Doxorubicin and Irinotecan in Patients with Solid Tumors (2009) (8)
Targeting vascular endothelial growth factor in patients with squamous cell lung cancer. (2012) (8)
Molecular prognostic factors in diffuse large B-cell lymphoma (2005) (8)
Management of patients with advanced non-small cell lung cancer: role of gefitinib (2010) (8)
SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study. (2020) (7)
Survival for nasopharyngeal cancer with distant metastatic disease at presentation. (2016) (7)
A Phase 1 – 2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC (2021) (7)
Warm-Antibody Autoimmune Hemolytic Anemia Developing after Thrombotic Thrombocytopenic Purpura (2002) (7)
Gene expression profiling in diffuse large B-cell lymphoma (2007) (7)
Systemic Treatment of Brain Metastases. (2017) (7)
Abstract A093: Phase 1/2 study of INCB054329, a bromodomain and extraterminal (BET) protein inhibitor, in patients (pts) with advanced malignancies (2018) (7)
Genomic landscape of squamous cell carcinoma of the lung. (2013) (7)
Prognostic factors influencing survival in solitary plasmacytoma (2009) (7)
nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy (2017) (7)
Impact of preoperative radiation on survival of patients with T3N0 >7-cm non-small cell lung cancers treated with anatomic resection using the Surveillance, Epidemiology, and End Results database. (2013) (7)
Acute graft-versus-host disease (aGVHD) presenting with an acquired lupus anticoagulant (2003) (7)
BRCAness in non-small cell lung cancer (NSCLC). (2014) (6)
Mutational Events in Lung Cancer: Present and Developing Technologies (2018) (6)
Abstract A078: FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies (2019) (6)
Lorlatinib: a new-generation drug for ALK-positive NSCLC. (2018) (6)
1256TiP Phase III study of pembrolizumab (Pembro) with concurrent chemoradiation therapy (CCRT) followed by pembro with or without olaparib (Ola) vs CCRT followed by durvalumab (Durva) in unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYLYNK-012 (2020) (5)
Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor treatment failure. (2019) (5)
Circulating cell-free tumor DNA (cfDNA) testing in small cell lung cancer. (2016) (5)
Multimodality Therapy for NSCLC. (2016) (5)
Association between depth of response and survival in patients with advanced‐stage non–small cell lung cancer treated with first‐line chemotherapy (2019) (5)
A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations (2021) (5)
Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer. (2020) (5)
Non-Hodgkin's lymphoma in the microarray era. (2004) (5)
A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC (2021) (5)
A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC). (2014) (5)
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial. (2020) (4)
Abstract P4-14-04: United States breast cancer mortality trends in young women according to race (2015) (4)
Results of a phase 1 study of SRF388, a first-in-human, first-in-class, high-affinity anti-IL-27 antibody in advanced solid tumors. (2021) (4)
KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49. (2019) (4)
Third-line chemotherapy with gemcitabine or docetaxel in patients with advanced non-small cell lung cancer (NSCLC) (2005) (4)
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC (2021) (4)
nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis (2021) (4)
A phase I study evaluating rovalpituzumab tesirine (ROVA-T) in frontline treatment of patients (pts) with extensive stage small cell lung cancer (ES-SCLC) (2019) (4)
Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction (2008) (4)
Miscellaneous agents. (2012) (4)
Heparin‐induced thrombocytopenia presenting with thrombosis of multiple saphenous vein grafts and myocardial infarction (2004) (4)
Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling. (2014) (4)
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. (2022) (4)
Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) (2018) (4)
Recent Advances in Lung Cancer: Summary of Presentations from the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2011 (2012) (4)
Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). (2017) (4)
MA08.06 Impact of Depth of Response (DpR) on Survival in Patients with Advanced NSCLC Treated with First-Line Chemotherapy (2017) (3)
A study of rovalpituzumab tesirine in frontline treatment of patients with DLL3 expressing extensive small cell lung cancer. (2017) (3)
Medullary thyroid cancer in the past, present and future: from bench to bedside (2011) (3)
Distinctive characteristics of extrapulmonary small cell carcinoma: A Surveillance Epidemiology and End Results (SEER) analysis (2008) (3)
CheckMate 592: a phase 2 exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC (2018) (3)
Chronic lymphocytic leukemia‐associated nephrotic syndrome caused by focal segmental glomerulosclerosis (2004) (3)
Multitargeted tyrosine kinase inhibitors in unselected patients with advanced non-small-cell lung cancer (NSCLC): impressions from MONET (the motesanib NSCLC efficacy and tolerability study). (2012) (3)
Precision medicine in lung cancer: the battle continues. (2016) (3)
P1.07-035 Circulating Cell-Free Tumor DNA (cfDNA) Testing in Small Cell Lung Cancer: Topic: Molecular Changes (2017) (3)
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers (2022) (3)
1359TiP RELATIVITY-104: First-line relatlimab (RELA) + nivolumab (NIVO) with chemotherapy vs nivo with chemotherapy in stage IV or recurrent non-small cell lung cancer (NSCLC): A phase II, randomized, double-blind study (2021) (3)
Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer. (2022) (3)
A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer (2008) (3)
Role of immune checkpoint blockers in patients with EGFR mutation. (2018) (2)
Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer (2022) (2)
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors (2022) (2)
Cell-Free DNA in Cancer Diagnosis and Follow Up (2019) (2)
A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3. (2021) (2)
Barriers for accrual to clinical trials in adult patients (pts) with thoracic malignancies. (2006) (2)
Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings. (2021) (2)
Best of the month: a roundup of articles published in recent months. (2010) (2)
First-in-human study of SRF388, a first-in-class IL-27 targeting antibody, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. (2022) (2)
Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer. (2022) (2)
Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation. (2021) (2)
Plasma cell leukemia: A SEER database analysis. (2009) (2)
nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study. (2018) (2)
Adjuvant chemotherapy for lung cancer: cisplatin doublets only? (2008) (2)
Interim results of a phase 1/2 study of JNJ-63723283, an anti-PD-1 monoclonal antibody, in patients with advanced cancers. (2018) (2)
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors (2020) (2)
Prevalence, clinical risk factors and outcomes of patients with lung cancer presenting with brain metastases. (2016) (2)
Squamous cell cancer of the head and neck (SCCHN) with distant metastasis at presentation (2008) (2)
Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies. (2021) (2)
Second-line therapy for esophageal cancer (2007) (2)
Improving survival for metastatic non-small cell lung cancer: A SEER database analysis from 1990 to 2005. (2009) (2)
High Remission Rates and Prolonged Progression Free Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma Treated with R-MACLOIVAM-T (2008) (2)
Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC) receiving viagenpumatucel-L (HS-110) plus nivolumab. (2020) (2)
Broadening response rates to PD-1 therapy in advanced lung adenocarcinoma: Viagenpumatucel-l (HS-110) in combination with nivolumab in the ongoing DURGA trial. (2016) (2)
QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer. (2018) (2)
Stage III pulmonary large cell neuroendocrine carcinoma (LNEC). (2016) (1)
A phase III trial-in-progress called REPLATINUM that compares RRx-001 + a platinum doublet to a platinum doublet in third-line or beyond small cell lung cancer. (2020) (1)
Rothman index as a predictor for type of discharge and readmission rates in a cancer hospital: The Yale experience. (2013) (1)
Novel cytotoxic agents. (2009) (1)
MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer (2019) (1)
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer (2022) (1)
Somatic mutations in mismatch repair pathway genes in non-small cell lung cancer. (2016) (1)
EP08.01-013 Ramucirumab plus Atezolizumab in Patients with Stage IV NSCLC Previously Treated with Immune Checkpoint Blockade (2022) (1)
P2.04-013 ElevatION:NSCLC-101 – A Phase 1b Study of PDR001 Combined with Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (2017) (1)
1220TiPMULTI-ARM, NONRANDOMIZED, OPEN-LABEL PHASE IB STUDY TO EVALUATE FP1039/GSK3052230 WITH CHEMOTHERAPY IN NSCLC AND MPM WITH DEREGULATED FGF PATHWAY SIGNALING. (2014) (1)
Phase-2 Study of R-MACLO-IVAM-T in Newly Diagnosed Mantle Cell Lymphoma. (2007) (1)
Non-small cell lung cancer in the new millennium: The effect of FDG-PET on stage distribution. (2006) (1)
An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC). (2018) (1)
Reply to C. Le Péchoux et al and B.S. Gill et al. (2015) (1)
Role for adjuvant chemotherapy in patients with resected small cell lung cancer. (2016) (1)
Characteristics of 1q amplification in adenocarcinoma of the lung (LUAD). (2014) (1)
Clinical predictive model for brain metastasis at presentation in patients with non-small-cell lung cancer (NSCLC). (2013) (1)
KEYLYNK-012: A Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy (CCRT) Followed by Pembrolizumab With or Without Olaparib vs. CCRT Followed by Durvalumab in Unresectable, Locally Advanced, Stage III Non‒Small-Cell Lung Cancer. (2021) (1)
Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012. (2021) (1)
MA09.09 First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC) (2017) (1)
Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (2005) (1)
Role for surgical resection in the multidisciplinary treatment of stage IIIB non-small cell lung cancer (NSCLC). (2014) (1)
Prognostic impact of malignant pleural effusion in patients with stage M1b non-small cell lung cancer. (2010) (1)
A phase 1b, open-label, single-arm study of cofetuzumab pelidotin (a PTK7-targeting antibody-drug conjugate) in patients with PTK7-expressing, recurrent non-small cell lung cancer (NSCLC). (2021) (1)
Survival following stereotactic body radiation therapy or conventionally fractionated radiation for definitive non-operative treatment of stage I non-small cell lung cancer: A review of the National Cancer Data Base. (2015) (1)
Abstract A52: Role of circulating tumor DNA (ctDNA) from liquid biopsy in early-stage NSCLC resected lung tumor investigation (LIBERTI) (2020) (1)
1616OMulticenter, nonrandomized, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy: results in malignant pleural mesothelioma (MPM) (2017) (1)
LBA48ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) (2017) (1)
Outcomes for stage IVA squamous cell carcinoma of the oral cavity according to staging subtypes. (2013) (1)
MA09.06 Viagenpumatucel-L Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary Data from the DURGA Trial (2017) (1)
Cancer of unknown primary (2008) (1)
Summary of presentations from the 46th annual meeting of the American Society Of Clinical Oncology (2010): focus on developmental therapeutics related to lung cancer. (2011) (1)
First interim exploratory analysis of immune response in patients with advanced non-small cell lung cancer receiving viagenpumatucel-l (HS-110) in combination with low-dose cyclophosphamide in an ongoing phase II trial. (2015) (1)
Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies. (2014) (1)
802 Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint blockade (2020) (1)
MA 10.02 Nab-Paclitaxel + Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2L+ (2017) (1)
FP07.13 Clinical Characteristics and Outcomes in Patients With KRAS G12C Mutated Non-Small Cell Lung Cancer (2021) (1)
Response to "Is post-operative radiotherapy of any benefit after R0 resection for N2 disease?". (2015) (1)
The role of adjuvant chemotherapy in stage IB non-small cell lung cancer: A decision, effectiveness, and cost-effectiveness analysis. (2017) (1)
Post-Operative Radiation Therapy for Non-Small Cell Lung Cancer Patients With Higher Positive to Examined Lymph Node Ratio is Associated With Improved Overall Survival. (2021) (0)
Incidence and Outcomes for Low Risk Myelodysplastic Syndrome: A Surveillance, Epidemiology and End Results (SEER) Study (2012) (0)
A phase Ib trial of anti-VEGFR/PDGFR vorolanib combined with immune checkpoint inhibitors (CPIs) in solid tumors. (2019) (0)
MicroRNA landscape in non-small cell lung cancer (NSCLC). (2014) (0)
Waldenstrom's Macroglobulinemia: A SEER Database Review From 1981-2005. (2009) (0)
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. (2023) (0)
Advanced NSCLC: Finding the right prescription for oncologist education. (2014) (0)
Comprar Manual Washington De Oncología 3ª Ed. | Ramaswamy Govindan | 9788416353460 | Wolters Kluwer España (2016) (0)
Efficacy of cetuximab-based second-line therapy in patients with metastatic head and neck squamous cell carcinoma (HNSCC) which progressed on gefitinib-based first-line therapy (2008) (0)
Characteristics of non-small cell lung cancer in patients under 40: a National Cancer Database (NCDB) Analysis 1998-2004: P1-036 (2007) (0)
Prognostic significance of tumor size in patients with stage III non-small cell lung cancer: A SEER database survey. (2009) (0)
IsThere a Role for Cetuximab in Non ^ Small Cell Lung Cancer? (2007) (0)
Contents Vol. 55, 2009 (2009) (0)
Role of Next-Generation Sequencing Technologies (2013) (0)
P2.03a-002 Patterns of Chemotherapy Use and Overall Survival (OS) of Patients with Stage IV Squamous Lung Cancer (SCC): Topic: Clinical Trials (2017) (0)
PS02.24 RRx-001 Priming in Patients with Previously Treated SCLC (QUADRUPLE THREAT): Topic: Medical Oncology (2017) (0)
How I Treat Patients with Metastatic Squamous Cell Lung Cancer (2013) (0)
Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx. (2012) (0)
Consolidation Chemotherapy Following Weekly Carboplatin-Paclitaxel Based Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer Is Associated With Improved Overall and Disease-Free Survival (2016) (0)
Nab-Paclitaxel plus Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2L+ (2017) (0)
Multi-arm, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy in malignant pleural mesothelioma (MPM). (2016) (0)
Pulmonary marginal zone lymphoma: A single center experience and review of the SEER database (2008) (0)
Central nervous system toxicities of chemotherapeutic (2014) (0)
RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer (2019) (0)
Quality of Life in Patients with Advanced NSCLC Treated in Second-or Third-Line with Nab-Paclitaxel plus Durvalumab: ABOUND. 2L+ (2018) (0)
Abstract 1137: Determination of a recommended Phase 2 dose (RP2D) for SRF388, a first-in-class IL-27-blocking antibody, in patients with advanced solid tumors (2022) (0)
Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer. (2020) (0)
2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592 (2022) (0)
Role of adjuvant radiation in patients with squamous cell carcinomas of the oral cavity. (2013) (0)
P2.03a-030 nab-Paclitaxel/Carboplatin Induction Therapy in Squamous (SCC) NSCLC: Interim Quality of Life (QoL) Results From ABOUND.sqm: Topic: Clinical Trials (2017) (0)
Immune Checkpoint Inhibition in Lung Cancer (2018) (0)
Prostaglandins and COX-2: Role in Antiangiogenic Therapy (2007) (0)
Subject Index Vol. 55, 2009 (2009) (0)
Prognostic impact of tumor (T) and lymph node (N) status in patients with metastatic non-small-cell lung cancer (NSCLC). (2013) (0)
P49.03 Chemoradiation with Cisplatin-Etoposide versus Carboplatin-Etoposide in Limited-Stage Small Cell Lung Cancer (2021) (0)
Impact of Preoperative Radiation on Survival of Patients With Node Negative, Very Large Non-small Cell Lung Cancers (T3N0) Treated With Anatomic Resection (2013) (0)
P1.05-047 Early Mortality in Patients with Non-Small Cell Lung Cancer Undergoing Adjuvant Chemotherapy: Topic: Neoadjuvant and Adjuvant Chemotherapy (2017) (0)
A phase I study of temsirolimus plus erlotinib in patients with refractory solid tumors. (2015) (0)
A090 Plasma Cell Leukemia: A SEER Database Analysis (2009) (0)
P1.01-93 Quality of Life in Patients with Advanced NSCLC Treated in Second- or Third-Line with Nab-Paclitaxel + Durvalumab: ABOUND.2L+ (2018) (0)
Split, low-dose docetaxel (D) and low-dose capecitabine (C) is an active regimen in metastatic breast cancer with minimal toxicity. (2006) (0)
MA 03.01 Nab-Paclitaxel ± CC-486 as Second-Line Treatment of Advanced NSCLC: Results from the ABOUND.2L+ Study (2017) (0)
Non-Small Cell Lung Cancer : Molecular Targets and Emerging Options for Care eDucAtiONAl (0)
ASCO 2016: Immune Checkpoint Inhibitors (2016) (0)
Targeted Therapy in Solid Tumors: Lung Cancer (2015) (0)
Phase I Trials Today (2015) (0)
Lack of Survival Improvement in Patients with Large Cell Lymphomas of T-Cell Phenotype: A SEER Analysis Comparing Outcomes According to Phenotype and Year of Diagnosis. (2007) (0)
FP07.11 Circulating Tumor DNA (ctDNA) Clearance as a Biomarker in Patients With Locally Advanced NSCLC Following Chemoradiation (2021) (0)
MINI01.20: Interim Quality of Life (QoL) Results from ABOUND.sqm: nab‐Paclitaxel/Carboplatin Induction Therapy in Squamous (SCC) NSCLC: Topic: Medical Oncology (2016) (0)
The role of surgery in stage IIIA non-small cell lung cancer: a decision and cost-effectiveness analysis (2014) (0)
Best of the month: A round up of articles published in recent months. (2011) (0)
A089 Solitary Plasmacytoma: A SEER Database Analysis of Survival (2009) (0)
Influence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck. (2012) (0)
Use of cancer immunotherapies in advanced NSCLC: Persistant challenges among oncologists. (2016) (0)
1369Pnab-paclitaxel/carboplatin (nab-P/C) induction therapy in squamous (SCC) non-small cell lung cancer (NSCLC): Interim safety results from ABOUND.sqm (2017) (0)
PP01.28 Tumor Engraftment is Prognostic for Disease Recurrence in Resected Non-Small Cell Lung Cancer (2023) (0)
Liquid Biopsies: New Technology and Evidence (2021) (0)
Use of chemotherapy for patients with stage IV non-small cell lung cancer. (2015) (0)
OA05.03 Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC) (2017) (0)
Multidisciplinary treatment for stage IIIA non-small cell lung cancer (NSCLC): Does institution matter? (2014) (0)
Effect of primary tumor size in patients with metastatic non-small cell lung cancer (NSCLC). (2013) (0)
Distinctive characteristics of non-small cell lung cancer in younger patients: A national cancer database (NCDB) analysis of patients under 40 years old (1998–2003) (2007) (0)
nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+) (2021) (0)
Epidermal Growth Factor Receptor , Human Epidermal Growth Factor Receptor 2 , and Human Epidermal Growth Factor Receptor 3 (2013) (0)
Second-line systemic therapy for esophageal cancer (2008) (0)
MA13.05 Nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Updated Results of the Phase III ABOUND.sqm Study (2019) (0)
Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations. (2023) (0)
Summary report from the 13(th) Annual Targeted Therapies of the Treatment of Lung Cancer Meeting. (2014) (0)
A roundup of recently published articles relevant to thoracic oncology. (2011) (0)
Evolving Treatment Options for Lung Cancer. (2017) (0)
A phase I/II multisite study of rucaparib and pembrolizumab maintenance therapy in stage IV non-squamous non–small cell lung cancer after initial therapy with carboplatin, pemetrexed, and pembrolizumab. (2022) (0)
Outcomes in 708 resected stage I non-small cell lung cancer (NSCLC) subjects and a prognostic index for relapse (2005) (0)
Multicenter phase II trial of RRx-001 in previously treated SCLC. (2019) (0)
P1.01-70 Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel + Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+) (2018) (0)
A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer (NSCLC) (NCT02299141). (2020) (0)
Acknowledgement of reviewers 2012 (2013) (0)
Patterns of Care and Survival for Early Versus Delayed Radiation Therapy (RT) in Limited-Stage Small Cell Lung Cancer (LS-SCLC): A Review of the National Cancer Data Base (2016) (0)
589 Xevinapant plus nivolumab in patients with advanced solid tumors who progressed on prior anti–PD-1/PD-L1 treatment: results of a dose-optimization, exploratory phase 1b/2 trial (2022) (0)
Cause of death among patients with non-small cell lung cancer treated with postoperative radiation therapy (PORT). (2021) (0)
First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors (2016) (0)
EGFRMutations in Non – Small-Cell Lung Cancer Find , Divide , and Conquer (2015) (0)
A roundup of articles published in recent months. (2012) (0)
Abstract B31: Viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) (2020) (0)
P09.26 Cause of Death in Patients with Squamous Cell Lung Cancer (SCC) Treated with Surgery (2021) (0)
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer (2018) (0)
Pan-cancer analysis of YAP1 expression as a predictive biomarker for cancer immunotherapy. (2022) (0)
Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC). (2019) (0)
Clinical characteristics and treatment outcomes of patients with pulmonary salivary gland-like tumors. (2016) (0)
Trends in Stage I Lung Cancer. (2022) (0)
HSV amplicon mediated augmentation of antitumor effects induced by tumor-specific T cells in the lymphopenic host. (2004) (0)
Survival and cause of death in patients with refractory anemias. (2013) (0)
Non-Hodgkin's Lymphoma in the Microarray Era Commentary (2004) (0)
Pulmonary neuroendocrine carcinomas: A population-based survey (2008) (0)
Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel plus Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+) (2018) (0)
Abstract 3414: Disruption of CREB-CREBBP association by 2-Naphthol AS-E phosphate induces cell cycle arrest and apoptosis in non-small cell lung cancer cells . (2013) (0)
Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors. (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Daniel Morgensztern?

Daniel Morgensztern is affiliated with the following schools:

Yale University
University of Miami

Daniel Morgensztern's Academic­Influence.com Rankings

Why Is Daniel Morgensztern Influential?

Daniel Morgensztern's Published Works

Published Works

What Schools Are Affiliated With Daniel Morgensztern?

Daniel Morgensztern's AcademicInfluence.com Rankings